Terns Pharmaceuticals, Inc.
General ticker "TERN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $512.6M (TTM average)
Terns Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 34.3%.
Estimated limits based on current volatility of 0.1%: low 52.60$, high 52.69$
Factors to consider:
- Total employees count: 66 (+43.5%) as of 2023
- Top business risk factors: Operational and conduct risks, Market competition, Labor/talent shortage/retention, Geopolitical risks, Market access challenges
- Current price 31.1% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.94$, 40.15$]
- 2026-12-31 to 2027-12-31 estimated range: [9.24$, 25.67$]
Financial Metrics affecting the TERN estimates:
- Negative: with PPE of -39.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.15 <= 0.07
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -7.80 <= -4.45
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 98.19 > 64.25
Short-term TERN quotes
Long-term TERN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $102.56MM | $101.87MM | $110.12MM |
| Operating Income | $-102.56MM | $-101.87MM | $-110.12MM |
| Non-Operating Income | $12.59MM | $13.28MM | $14.50MM |
| R&D Expense | $63.50MM | $70.11MM | $77.89MM |
| Income(Loss) | $-89.97MM | $-88.59MM | $-95.63MM |
| Taxes | $0.24MM | $0.26MM | $0.58MM |
| Profit(Loss)* | $-90.21MM | $-88.85MM | $-96.21MM |
| Stockholders Equity | $255.37MM | $345.87MM | $1,006.52MM |
| Assets | $268.52MM | $363.93MM | $1,025.08MM |
| Operating Cash Flow | $-67.39MM | $-70.02MM | $-82.18MM |
| Capital expenditure | $0.05MM | $0.04MM | $0.00MM |
| Investing Cash Flow | $-37.99MM | $-12.41MM | $-298.04MM |
| Financing Cash Flow | $41.95MM | $164.00MM | $743.51MM |
| Earnings Per Share** | $-1.27 | $-1.12 | $-1.03 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.